Details for Patent: 9,358,235
✉ Email this page to a colleague
Which drugs does patent 9,358,235 protect, and when does it expire?
Patent 9,358,235 protects TURALIO and is included in one NDA.
This patent has twenty-two patent family members in fifteen countries.
Summary for Patent: 9,358,235
| Title: | Kinase modulation, and indications therefor |
| Abstract: | The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof. |
| Inventor(s): | Gideon Bollag, Klaus-Peter Hirth, Prabha N. Ibrahim, Paul Lin, Brian West |
| Assignee: | Daiichi Sankyo Inc |
| Application Number: | US13/802,106 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,358,235
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY | ⤷ Start Trial | ||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,358,235
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013235298 | ⤷ Start Trial | |||
| Australia | 2017254821 | ⤷ Start Trial | |||
| Brazil | 112014023162 | ⤷ Start Trial | |||
| Canada | 2867918 | ⤷ Start Trial | |||
| China | 104703623 | ⤷ Start Trial | |||
| Eurasian Patent Organization | 029676 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
